Send a text

In this episode of Causes or Cures, Dr. Eeks sits down with Benjamin Lightburn, CEO of Filament Health, to explore the key differences between natural and synthetic psychedelics—and why those differences matter. Ben breaks down how Filament Health develops its natural psychedelic medicines, shares insights from ongoing clinical trials with top academic institutions, and discusses the early results. He also explains how Filament plans to bring these treatments to market and what sets them apart in the rapidly growing psychedelic space.

Ben is a pioneer in natural drug development, having co-founded Filament Health to create the first-ever safe, naturally derived psychedelic medicines for conditions like substance use disorder. With 15 clinical trials underway across North America and Europe and a business now valued at $210M, Filament is making waves in the industry. Before this, Ben built and sold a successful natural extraction startup, Mazza Innovation, securing major deals with multinationals before its $26M acquisition.

Tune in for a fascinating deep dive into the future of psychedelics—where nature meets science!

You can contact Dr. Eeks at bloomingwellness.com.
Follow Eeks on Instagram here.
Or Facebook here.
Or X.
On Youtube.
Or TikTok.
SUBSCRIBE to her monthly newsletter here.

Support the show